Why did AKTX's EPS stay flat in recent quarters?

The EPS of AKTX has remained flat in recent quarters due to a combination of factors: 1. **Operating Expenses**: The company's operating expenses, including research and development, general and administrative costs, and merger-related costs, have been increasing. These expenses are likely impacting the net profit, thereby flattening the EPS. 2. **Cash Position**: As of June 30, 2024, Akari Therapeutics had cash of $4.2 million, compared to $3.8 million as of December 31, 2023. The company's cash position is relatively stable, which suggests that the fluctuations in expenses are not being offset by significant changes in revenue or other income sources. 3. **Merger and Acquisition Activity**: The company has been involved in merger and acquisition activities, including the proposed merger with Peak Bio. Such activities can lead to significant expenses and potential disruptions to the business, which may impact the financial performance and, consequently, the EPS. In summary, the flat EPS of AKTX in recent quarters is primarily due to the increasing operating expenses and the impact of merger and acquisition activities, rather than changes in the revenue or other income sources.